We found that it is essential for physicians to explain potential cancer risks to patients before starting long-term immunosuppressive therapy and to conduct routine checks for MCC and other side effects. TNF inhibitors (infliximab, adalimumab, etanercept, and golimumab) were all associated with MCC development. Women constituted the majority of cases and most were elderly.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- ulcerative colitis
- ankylosing spondylitis
- newly diagnosed
- ejection fraction
- primary care
- chronic kidney disease
- prognostic factors
- human health
- peritoneal dialysis
- papillary thyroid
- polycystic ovary syndrome
- squamous cell carcinoma
- disease activity
- stem cells
- pregnant women
- middle aged
- cell therapy
- patient reported outcomes
- young adults
- climate change
- smoking cessation
- hidradenitis suppurativa